CELG-RI
Bristol-Myers Squibb Company Ce
NYSE · Healthcare · Drug Manufacturers - General · US
$0.14
−6.69%Year over year
Reported trailing growth
- Revenue
- +1.8%
- EBITDA
- +13.5%
- EBIT
- +53.2%
- EPS
- +33.1%
- Free cash flow
- -9.0%
- Operating cash flow
- -7.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +1.4%
- EBITDA
- +0.0%
- EBIT
- +18.4%
- Net income
- +3.7%
- EPS
- +5.3%
- Free cash flow
- +2.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026